Overview

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well PR-104 works in treating patients with previously untreated or relapsed small cell lung cancer (SCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Proacta, Incorporated